MedTrace Logo

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

NCT00035334 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2006-02-14

No results posted yet for this study

Summary

The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical improvement/worsening of both renal and gastrointestinal functions.

Conditions

Interventions

DRUG

NC-503 (Anti-amyloidotic (AA) Agent)

Sponsors & Collaborators

  • FDA Office of Orphan Products Development

    collaborator FED

  • Bellus Health Inc. - a GSK company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Completion
2004-12-31

Countries

  • United States
  • Finland
  • France
  • Israel
  • Italy
  • Lithuania
  • Netherlands
  • Poland
  • Russia
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00035334 on ClinicalTrials.gov